1	James Robert Noblin (State Bar No. 114 GREEN & NOBLIN, P.C.	442)
2	4500 East Pacific Coast Highway Fourth Floor	
3	Long Beach, California 90804 Telephone: (562) 391-2487	
4	Facsimile: (415) 477-6710 Email: gnecf@classcounsel.com	
5		
6	Robert S. Green (State Bar No. 136183) GREEN & NOBLIN, P.C.	
7	2200 Larkspur Landing Circle, Suite 101 Larkspur, CA 94939	
8	Telephone: (415) 477-6700 Facsimile: (415) 477-6710	
9	Email: gnecf@classcounsel.com	
10	Attorneys for Plaintiffs	
11		
12	UNITED STATES DISTRICT COURT	
13	CENTRAL DISTRIC	T OF CALIFORNIA
14		
15	JILL PATT, D.V.M., and LITTLE	Case No.: 8:18-cv-01689-JLS-DFM
16	CRITTERS VET, LLC, individually and on behalf of all others similarly	SECOND AMENDED COMPLAINT
17	situated,	FOR RESTITUTION, INJUNCTION
18	Dlaintiffa	AND DAMAGES FOR VIOLATIONS OF CAL. BUS. &
19	Plaintiffs,	PROF. CODE § 17200, BREACH OF
20	VS.	CONTRACT, and VIOLATION OF SECTION 2 OF THE SHERMAN
21	ANTECH DIAGNOSTICS, INC.	ACT
22	Defendant.	CLASS ACTION
23	Defendant.	CLASS ACTION
24		DEMAND FOR JURY TRAIL
25		
26		
27		
28		

SECOND AMENDED COMPLAINT 8:18-cv-01689-JLS-DFM

Little Critters Jill Patt, D.V.M., and Little Critters Vet, LLC, on behalf of themselves and all others similarly situated, allege the following:

I. PARTIES

A. Individual and Representative Little Critters

- 1. Dr. Jill Patt, D.V.M. is a veterinarian practicing through the auspices of Plaintiff Little Critters Vet, LLC, in Gilbert, Arizona.
- 2. Little Critters Vet, LLC, is a limited liability company formed under Arizona law that operates a veterinary office and practice under the tradename Little Critters Veterinary Hospital in Gilbert, Arizona. Dr. Jill Patt and Little Critters Vet, LLC are sometimes collectively referred to below as "Little Critters".

B. Antech

3. Antech Diagnostics, Inc. ("Antech") is a California corporation with its corporate headquarters located at 17620 Mt. Hermann Street, Fountain Valley, California 92708. It is a subsidiary of VCA, Inc., sometimes operating under the tradename VCA Antech, which began as an owner and operator of veterinary hospitals, but which now also holds subsidiaries operating in a number of pet health sectors. On January 9, 2017, Mars, Inc. announced that it was purchasing VCA, Inc. for approximately \$9.1 billion and, on September 12, 2017, announced that the acquisition had been completed.

II. JURISDICTION AND VENUE

- 4. This Court has original jurisdiction of this action under the Class Action Fairness Act of 2005. Pursuant to 28 U.S.C. §§ 1332(d)(2) and (6), this Court has original jurisdiction because the aggregate claims of the members of the putative Class exceed \$5 million, exclusive of costs, and each Plaintiff is a citizen of a different state than Defendant.
- 5. The Central District of California has personal jurisdiction over Antech because Antech is authorized or registered to do business and operate in

6. Venue is proper in this District pursuant to 28 U.S.C. § 1391, because Antech's headquarters are in this District and it transacts substantial business within this District. Antech's form contracts for selling veterinary diagnostic reference laboratory testing services include a venue provision providing, "Each of the parties hereto hereby irrevocably consents and submits to the exclusive personal jurisdiction of United States District Court for the Central District of California."

III. SUMMARY OF THE ACTION

7. Just like medical doctors providing care for human patients, veterinarians use and rely upon a wide range of laboratory tests to diagnose and treat their animal patients. Antech is one of two major providers of diagnostic reference laboratory testing services to veterinarians in the United States. In their marketing materials, Antech states:

No one better understands the importance of quality patient care and the value of accurate dependable testing than VCA ANTECH . . . Dependable testing is more than technology; accurate and dependable results rely on highly skilled and trained technicians. Each and every ANTECH Laboratory Technician is under daily QA/QC programs designed to ensure accurate results while receiving annual mandatory testing to insure their skills and knowledge are second to none.

8. To obtain Antech diagnostic reference laboratory testing services, veterinarians typically enter into a contract substantially the same in form as that reached between Little Critters and Antech, which is attached hereto as Exhibit A (the "Contract"), although the dollar figures vary from veterinarian to veterinarian. These agreements are contracts of adhesion, to which Antech requires agreement rather than one with the substantive terms negotiated other than dollar amounts, an approach Antech has consistently taken for decades.

- 9. The terms accuracy and precision are not subjective when applied to diagnostic laboratories. Rather, as alleged below, extensive academic literature and industry guidelines have been developed to measure accuracy and precision in statistical terms. Practitioners consider testing results to be dependable when they meet or exceed these guidelines for accuracy and precision.
- 10. Antech's diagnostic laboratory services and results are woefully below applicable guidelines. Indeed, the quality of Antech's services and results are substantially worse than that of competitors. As a result, veterinarians under contract with Antech are put at risk of providing unacceptable levels of veterinary care to their patients due to receiving inaccurate, undependable and imprecise laboratory test results from Antech.
- 11. Consequently, veterinarians were deceived when Antech marketed itself as providing accurate, precise, and dependable laboratory services and results that were "second to none."
- 12. Rather than compete openly in terms of price and quality of service, Antech has shielded itself from the competitive discipline of the marketplace by steering veterinarians to enter into exclusive dealing contracts with onerous terms and by undertaking other efforts to attempt to monopolize the market for veterinary diagnostic reference laboratory testing services in the United States.

Consequently, competition for veterinary diagnostic reference laboratory testing services in this country is restrained, and veterinarians and their patients receive poorer quality at a higher price than would pertain in a competitive marketplace. For the sake of veterinarians and their patients, Little Critters seek to represent a class of those who contracted with Antech to remedy these injustices. Plaintiffs excluded from this Second Amended Complaint the Counts that the Court dismissed with prejudice in its May 18, 2020 Order Granting in Part and Denying in Part Defendant's Motion to Dismiss Claims and Strike Class Allegations. Plaintiffs hereby reserve their right to appeal the dismissal with

11

12

10

1

2

3

4

5

6

7

8

9

13 14

15

17

16

18 19

20

21 22

23

24 25

26

27 28

IV. COMMON SUBSTANTIVE ALLEGATIONS

prejudice when ripe for appeal.

- **Veterinarians Need Diagnostic Reference Laboratory Testing Services, Including Test Results** Α.
- There are three distinct types of laboratories in the veterinary field. 13. First, most veterinarians can perform certain laboratory tests "in-house" at their offices by using microscopes, blood machines, urine analyzers and the like. Tests typically performed in-house include blood count, blood chemistry, urine testing, and microscopic evaluation of skin scrapes and ear swabs. Second, there are clinical laboratories, typically under the auspices of a university, which support research and teaching designed to improve the practice of veterinary care over the long term. Third, companies such as Antech operate what are called veterinary diagnostic reference laboratories that provide laboratory testing, services and results to veterinarians, including some tests that a veterinarian cannot typically perform in-house. Examples of such tests include those designed to detect the presence of Aspergillus antibodies in birds, Pasteurella PCR in rabbits, Ehrlichia PCR in dogs and Chlamydophila in cats.

/////

14. As a result, virtually all private veterinary practices contract with diagnostic reference laboratory companies to obtain tests, services and results. These arrangements typically establish the method by which the veterinary practice will convey test samples to the diagnostic reference laboratory, most often by scheduled pick-up by the laboratory with overnight shipping for other tests, where appropriate. The diagnostic reference laboratory will then conduct a test on the sample and convey the result to the veterinary practice, often – as is the case with Antech – by transmission via the Internet by interfacing with the veterinary practice's electronic medical records. The laboratory company's staff is also supposed to be available to the veterinary practice to provide support, answer questions, and respond to concerns. When dealing with companies other than Antech, veterinary practices typically pay a specified price for each test and then bill their customer for those tests. Veterinary practices also rely heavily on test results in diagnosing patients and formulating treatment plans and options.

B. Antech Imposes Onerous Exclusive Contracts on Veterinary Practices

15. Antech requires veterinarians to whom it provides what it contends are preferred pricing and priority customer service for its laboratory testing services to sign a form contract it calls the "Exclusive Laboratory Services Agreement" (the "Exclusive Agreement(s)"). Attached as Exhibit A hereto is the first seven pages of the one signed by Dr. Patt on July 6, 2017, not including pages 8 through 10 consisting of an Annex relating to prices, discounts, and credits. The Exclusive Agreements contain a confidentiality provision purporting to prohibit veterinarians from disclosing any terms of the agreement and declaring that a breach of any of the promises in the agreement will result in irreparable and continuing damage to Antech Diagnostics for which there shall be no adequate remedy at law. Exh. A, Page 3, ¶ 7. That confidentiality provision contains an

- 16. The confidentiality clause in the Exclusive Agreements, particularly when combined with the "loan" and other purported discounts contained in those agreements, discussed below, create a conflict of interest between veterinarians and their clients because, under California state licensing rules, veterinarians are required to disclose the actual price charged by the laboratory for results.
- 17. The confidentiality provisions in the Exclusive Agreements, in conjunction with other provisions and practices discussed below, were designed to and have the effect of inhibiting and prohibiting veterinarians from discussing amongst themselves their relations with Antech. As a consequence, the ability of veterinarians to mitigate the impact of Antech's onerous practices by ameliorating conduct has been impaired.
- 18. Another factor making it difficult for veterinarians to communicate about, or even discern, Antech's conduct is the way in which Antech structures its periodic statements to veterinarians so that the veterinarian has no means of knowing if Antech is honoring the preferred pricing specified in the Exclusive Agreements. Specifically, Antech simply provides a lump sum discount at the bottom of its statements with no information about what was actually charged to the veterinary practice per each individual test.
- 19. Antech's Contract with Little Critters has an initial term of 6 years, and its Exclusive Agreements have terms ranging from 5 to 7 years. The

- Exclusive Agreements require that veterinarians use Antech for almost their entire diagnostic reference laboratory testing requirements during the term of the Exclusive Agreement. The Exclusive Agreements state, "During the Term, Practice Owner shall cause all Laboratory Services that are to be performed for and on behalf of the Practice(s), to be performed by a veterinary diagnostic laboratory owned or operated by Antech Diagnostics." Exh. At, Page 2. There are certain limited exceptions to the exclusivity provision, such as for tests that Antech does not perform, or where the test prices are less than 10% of all fees for such services. *Id*.
- 20. Antech's Exclusive Agreement also sets a minimum dollar amount per year that each practice must pay Antech. For Little Critters, the Contract provided for purchase, after application of all discounts and credits, veterinary diagnostic laboratory services from Antech in "an aggregate amount of not less than \$24,000" for each 12 month period following the July 1, 2017 Effective Date of the contract. Exh. A, Page 2. These annual minimum requirements, a standard feature of Antech's Exclusive Agreements, affect the incentives Antech will pay. Specifically, Antech salesmen endeavor to get veterinarians to agree to higher annual minimum limits in order to obtain greater incentive payments, lower prices, and greater discounts.
- 21. From the outset of the Contract through May, 2018, Little Critters exceeded the aggregate amount of purchases from Antech for each month on a pro-rated basis by much more than the minimum required under the Contract.
- 22. Antech's form Exclusive Agreement also provides for a loan to the practice owner for a period equal to the exclusive term. For Little Critters, the Contract provided a loan in the amount of \$12,000 for a period of 6 years at an annual interest rate of 7%. Exh. A, Page 5. The "loan" is actually an element of pricing and a mechanism to further incentivize practice owners to comply with the exclusivity requirements. Thus, the loan includes a "forgiveness" provision

- 23. The Exclusive Agreements contain "evergreen clauses," under which the contract renews for an additional 24 months unless the veterinarian provides written notice of non-renewal at least one year prior to the end of the term. Exh. A, Page 3, ¶ 3. Antech makes it difficult for veterinarians to know if they have complied with this clause. For example, Antech provides no reminder of the approaching deadline for providing notice and is evasive about whether it will accept emails as written notice. Nor does Antech specify to whom in the organization written notice must be provided. For example, Dr. Patt had to communicate with Antech multiple times before finally obtaining confirmation that she had exercised her notice rights.
- 24. Paragraph 2 of the Standard terms and conditions in the Exclusive Agreement states, "All Laboratory Services provided by Antech Diagnostics pursuant to this Agreement are provided in accordance with and subject to all terms and conditions set forth in the ANTECH Service Directory in effect at the time the Laboratory Services are performed." Exh. A, Page 3, ¶ 2. The last Service Directory published by Antech states, "In accepting work, we warrant that we shall provide services in a professional manner by qualified personnel, and we warrant the accuracy of the test results for the specimen submitted."

C. Antech Coerces Veterinarians to Remain in Contractual Relations

25. Antech uses force, coercion, threats, intimidation and federal lawsuits to keep its veterinarian clients in line paying their annual minimums and exclusively using Antech's services. Antech has filed over 55 federal lawsuits against its veterinarian clients since February 2013.

- 26. Prior to filing suit, Antech sends a threatening demand letter from its counsel to the veterinarians demanding huge sums of money not justified under the Exclusive Agreement and declaring that Antech wins these cases when they are filed. The letter sent to Little Critters, dated August 15, 2018, is attached as Exhibit B, without the copy of the Exclusive Agreement that was attached to the original of Exhibit B.
- 27. In its letter to Little Critters, Antech demanded payment, as follows: "You owe \$298,704.76 which represents the amount that Antech has been damaged by your breach, including the return of the \$24,000 incentive.

 Accordingly, I will expect that a check made payable to 'Antech Diagnostics' in the amount of \$1298,704.76 [sic] be delivered to my office no later than the close of business on August 24, 2018." The letter does not explain or itemize how Antech determined that it was entitled to almost \$300,000 or how it could be reasonable to require a veterinarian to pay that amount of money nine days from the date the letter was drafted. In most cases, Antech simply calculates the amount that the veterinarian would have paid if they had exclusively used Antech and made the minimum required purchases for the rest of the term, thus claiming 100% of those payments as "lost profits," without regard to the fact that is not how lost profits are calculated.
- 28. Before Antech sent the demand letter to Dr. Patt, she had worked with Antech for over six months elaborating her concerns and looking for ways to improve results. She had also suggested modifying the Contract to allow her to send those tests in which she had lost confidence in Antech to competing laboratories, but Antech ignored or rejected those efforts.
- 29. In one case Antech litigated in Maryland, it claimed damages of \$273,000 over the remaining life of the contract. The Court in a Memorandum Opinion stated that Antech's "chance of actually recovering that amount appears remote."

- 30. Antech's demand letters are drafted to maximize the *in terrorem* effect on the recipients in the hope that they will generate further payments to Antech and prevent the recipients from determining the valid defenses they may have.
- 31. Antech also requires the use of nondisclosure agreements in its settled litigation to prevent the veterinarians from putting each other on notice about Antech's tactics and its continuous provision of false lab results.
- 32. One veterinarian stated that they had been threatened with a slander suit from Antech upper management if they posted on the online forum with complaints similar to Plaintiff Dr. Patt's complaints.
- 33. Antech threatened to sue another veterinarian with similar complaints and indicated that Antech would seek all of his records, including the posts on the veterinarian's Internet forum. Antech also sent an investigator to take photographs of the IDEXX box on his door as proof that he was not exclusively using Antech and took video of the IDEXX driver picking up the samples. (IDEXX is Antech's principal competitor.)
- 34. Antech also uses the economic threat of litigation, rather than the merits of prospective litigation, to coerce veterinarians into abiding by the Exclusive Agreement. As a large company that has extensive experience suing under the Exclusive Agreement, Antech knows that it can easily afford the costs of each case much more readily than can an individual or small practice veterinarian, who has no such experience. Consequently, Antech expects that many veterinarians will back down rather than follow-through on their desire to end contractual relations with Antech, an expectation that has frequently come to pass.
- 35. A factor increasing Antech's ability to use the economic threat of litigation, rather than the merits of prospective litigation, to coerce veterinarians into remaining in contractual relations with Antech is the governing law and

venue provision in the Exclusive Agreement. *See* Exhibit A, Page 5 ¶ 9 & Page 9 ¶ 12, stating that any disputes arising out of the arrangement will be governed by California law and subject to the venue of this Judicial District. Antech requires veterinarians all over the country to sign agreements containing these clauses, increasing the degree to which Antech is more familiar with the litigation that would ensue than would be the veterinarians, especially those in other states whose attorneys are not licensed to practice in California. As a consequence, both Antech and the veterinarians know that any resulting litigation will be relatively cheaper for Antech and more expensive for the veterinarians than if the Exclusive Agreement was governed by the law of the state in which the veterinarian operated and/or in which the Antech lab performing the tests were located.

36. It has been documented in a number of sources that veterinarians tend to be a very law abiding group relative to other medical professionals and the population at large. This fact makes Antech's practice of suing large numbers of veterinarians for breach of contract even more suspicious and indicative of misconduct on Antech's part.


D. Antech Falsely Represents that it Provides Accurate, Precise, and Dependable Lab Results

37. Antech represents that its lab results are of high quality and can be trusted because, among other things, it claims to employ high quality staff. One such online representation is: "No one better understands the importance of quality patient care and the value of accurate, dependable diagnostic testing than VCA ANTECH. ... Dependable testing is more than technology; accurate and dependable results rely on highly skilled and trained technicians. Each and every ANTECH Laboratory Technician is under daily QA/QC programs designed to ensure accurate results while receiving annual mandatory testing to insure their skills and knowledge are second to none."

- (http://www.antechdiagnostics.com/main/becomeanantechclient.aspx). Plaintiff Dr. Patt, acting within the course and scope of her relationship with Plaintiff Little Critters Vet, LLC, saw and relied on this representation and other Antech representations of the quality of Antech's testing services and results prior to entering into the Contract with Antech. This representation was intended to and did create the false impression that Antech manages its laboratory technical staff in such a way as to insure accurate, precise and dependable test results. This impression is false for the reasons described below.
- 38. Antech produces a steady stream of statements to veterinarians touting quality, such as the line on the front page of its 2019 fee schedule declaring that Antech is, "Defining the Standard of Excellence" at its diagnostic labs. Antech marketing materials also stated their laboratories are "state-of-the-art." Antech marketing materials also stated that Antech sets "the standard for reference laboratory excellence." Dr. Patt, acting within the course and scope of her relationship with Plaintiff Little Critters Vet, LLC, saw and relied on these representations prior to entering into an agreement with Antech.
- 39. The Agreement states, "All Laboratory Services provided by Antech Diagnostics pursuant to this Agreement are provided in accordance with and subject to all terms and conditions set forth in the ANTECH Service Directory at the time." Exh. A, Page 3, ¶ 2. During all relevant times, the ANTECH Service Directory stated with respect to Antech, "In accepting work, we warrant that we shall provide services in a professional manner by qualified personnel, and we warrant the accuracy of the test results for the specimen submitted." It also stated, "ANTECH Diagnostics is dedicated to quality control (QC) and (QA) that are unsurpassed in the industry." It also stated that Antech's techniques "not only assure compliance and uniformity amongst our teams, but also provide peace of mind for our clients from the knowledge that we continuously strive for measurable improvements."

E. There Are Objective Guidelines for Evaluating Error, Accuracy, and Precision as Measures of the Dependability of Veterinary Diagnostic Reference Laboratory Testing

40. Accuracy is defined by the American Society of Veterinary Clinical Pathologists (ASVCP) as the closeness of agreement between the results of a measurement and the true concentration of the analyte (*i.e.*, hitting the bulls eye of the target). *See* Harr KE, Flatland B, Nabity M, Freeman KP., *ASVCP Guidelines: Allowable Total Error Guidelines for Biochemistry*, 42(4) <u>Veterinary Clinical Pathology</u>, 2013 Dec;42(4):424-36 (Dec. 2013). Accuracy is the opposite of inaccuracy (and inaccuracy is also sometimes called "bias"), as depicted below. The more accurate the measured value, the closer the measured line is to the reference value.



Bias is calculated using the formula: bias (%) = ([mean measured – mean target]/mean target) x 100.

41. Precision is defined as agreement between independent, repeated results obtained from the same specimen under specified conditions. It is represented by the standard deviation (in units of the test) or coefficient of variation (in units of percent) calculated from performance testing data. (*See* Nabity MB, Harr KE, Camus MS, Flatland B, Vap LM., *ASVCP Guidelines: Allowable Total Error Hematology*, 47(1) Veterinary Clinical Pathology, 9-21 March 2018). Error in precision and accuracy are called imprecision and bias and

can be quantified. These are combined in Allowable Total Error = 2 x Coefficient of Variation (aka imprecision) + Bias (in % terms). Both CLIA and ASVCP have set Allowable Total Error, defined as a quality requirement that sets a limit for combined imprecision (random error) and bias (inaccuracy, or systematic error) that are tolerable in a single measurement or single test result to ensure clinical usefulness. Allowable total error is an established benchmark in the field.

- 42. In considering the accuracy and precision of diagnostic reference laboratory results, it is useful to divide errors and potential errors into three categories. The first is "pre-analytical," encompassing errors that occur before the sample is analyzed in the laboratory. The most commonly reported types of pre-analytical error are: a) missing sample and/or test request, b) wrong or missing identification, c) contamination from infusion route, d) hemolysed, clotted, and insufficient samples, e) inappropriate containers, f) inappropriate blood to anticoagulant ratio, and g) inappropriate transport and storage conditions. The second category is "analytical," resulting typically from false positives or false negatives in the test itself due to bias, imprecision, and possible interferences. The third category is post-analytical, resulting primarily from data entry error.
- 43. In categorizing analytical errors further, two measures are important in the field for determining the clinical usefulness of the analysis performed by a laboratory. The first is "diagnostic sensitivity," which is essentially the statistical measure for the proportion of actual positives that are correctly identified. The second is "diagnostic specificity," which is essentially the statistical measure for determining the proportion of actual negatives that are correctly identified. Practitioners consider testing results to be dependable when the diagnostic sensitivity and specificity is high enough to meet acceptable guidelines in clinical practice.

/////

- 44. More specific objective guidelines applicable to veterinary diagnostic reference laboratories have also been developed. For example, an Antech employee (at the time) was the lead author of an academic journal article outlining ASCVP consensus quality assurance guidelines. Gunn-Christie RG, Flatland B, Friedrichs KR, Szladovits B, Harr K, Ruotsalo K, Knoll J, Wamsley H, Freeman K.P., ASVCP Quality Assurance Guidelines: Preanalytical, Analytical, and Postanalytical Factors for Clinical Chemistry, Urinalysis, and Cytology in Veterinary Laboratories 41 Vet Clin Pathol. 18–26 (2012). The article provides minimal guidelines for quality assurance and quality control for veterinary laboratory testing and a basis for laboratories to assess their current practices. Among the practices identified as setting the baseline minimum are the following:
 - · All verbal or written feedback, including complaints and suggestions, should be documented and forwarded to the appropriate level of management. Corrective actions in response to feedback must be documented and organizational reviews conducted to ensure timely and appropriate follow-up.
 - Personnel conditions should be comfortable and appropriate for computer data entry, data transcription, handling specimens, specimen disposal, and all other specimen-processing tasks with special consideration given to repetitive work.
 - · Personnel should meet training requirements necessary for specific areas of the laboratory. The laboratory should be staffed appropriately to meet the workload.
 - An instrument performance log should be kept for each instrument. If possible, monitoring should include participation in an external proficiency or quality assurance program specific to veterinary diagnostic laboratories.

- Appropriate use of retest criteria should be used. Documentation of retesting should be included on the worksheet and the report or, if necessary, on the corrected report.
- · Adequate training of analysts performing microscopic examination of urine specimens from animals is necessary and should be documented.
- As it relates to cytology, the individual who interprets findings in veterinary specimens, preferably a board-certified veterinary pathologist, should have documented cytopathology training and good working knowledge of cytologic findings from all species and cytologic specimen types expected to be received by the laboratory and evaluated. The individual should be available to communicate with clients about important pre-analytical, analytical, and post-analytical factors regarding the cytologic specimens.
- Regarding clinical chemistry, an instrument performance log should be maintained for each analyzer. External monitoring should include participation in an external proficiency or quality assurance program specific to veterinary diagnostic laboratories.
- Validation of QC rules and procedures is recommended to ensure that errors in precision and accuracy are identified. Unidentified errors may invalidate the clinical use of the test results.
- The laboratory should establish a procedure for a two person review of specimen quality and results by technologists, supervisors, or pathologists prior to finalization and release of results. An explicit review may be stipulated for problematic tests or for certain specimen characteristics or may be based on the clinical significance of test results.

/////

27 /////

28 /////

- The laboratory should keep a copy of all reports and any accompanying worksheets. Reports should be initialed and dated by the technician or pathologist involved in performing or interpreting any stage of the procedures.
- 45. Antech's failure to comply with these minimal quality assurance guidelines is demonstrated through the incorrect results provided to Little Critters and other veterinary practices, and by Antech's changing records without documenting corrections. Likewise, comments by Antech employees establish that Antech has not met the minimal guidelines for staffing required by these guidelines. The documentation required by these guidelines is exclusively in the hands of Antech and not available to Little Critters or other veterinarians.¹
- 46. Pursuant to these guidelines and practices, efforts have been made to reduce error rates at veterinary laboratories to levels far below those that pertain at Antech. For example, one laboratory was able to implement an error management system that reduced its error rate from 1.3% to 0.7%. Hooijberg E, Leidinger E, Freeman K., *An Error Management System in a Veterinary Clinical Laboratory*, 24(3) J. Vet. Diagn. Invest., 458-68 (May 2012). Similarly, the University of Florida has installed a new LIMS system to decrease its error rate

Numerous other articles also articulate objective guidelines for achieving accuracy and precision in veterinary diagnostic reference laboratories. See, e.g., Flatland, B., Camus, M.S. and Baral, R.M., Analytical Quality Goals — a Review, 47(4) Veterinary Clinical Pathology, 47(4), pp.527-538 (2018); Nabity MB, Harr KE, Camus MS, Flatland B, Vap LM. 2018 47(1) ASVCP Guidelines: Allowable Total Error Hematology, 47(4) Vet. Clin. Pathol. 9-21 (March, 2019); Friedrichs, K R, Harr, KE, Freeman, KP, Szladovits, B, Walton, RM, Barnhart, KF, and Blanco-Chavez, J.. ASVCP Reference Interval Guidelines: Determination of de Novo Reference Intervals in Veterinary Species and Other Related Topics, 41 Vet. Clin. Pathol. 441–453 (2012); Vap LM, Harr KE, Arnold JE, Freeman KP, Getzy K, Lester S, Friedrichs KR. ASVCP Quality Assurance Guidelines: Control of Preanalytical and Analytical Factors in Veterinary Laboratories Related to Hematology for Mammalian and Non-Mammalian Species, Hemostasis, And Crossmatching, 41 Vet. Clin. Pathol. 8–17 (2011); Flatland, B., Freeman, K. P., Friedrichs, K. R., Vap, L. M., Getzy, K. M., Evans, E. W. and Harr, K. E., ASVCP Quality Assurance Guidelines: Control of General Analytical Factors in Veterinary Laboratories, 39 Vet. Clin. Pathol. 39: 264–277 (2010).

from a level of 4.5%. As can be seen from these examples, overall laboratory error rates including preanalytical, analytical and postanalytical rates are quite low in other veterinary diagnostic reference laboratories.

47. Review of error tracking data in other veterinary diagnostic reference laboratories has repeatedly shown that, when error collection was based on clinician complaints, like Little Critters' experience here, the number was very low, on the order of 0.05% of all test results. When a careful review of the whole working process was performed, the number of errors increased substantially to 0.5% of all test results, *i.e.*, clinician detected error represents "the tip of the iceberg" of error actually occurring in the laboratory. (Bonini P, Plebani M, Ceriotti F, Rubboli F. *Errors In Laboratory Medicine*, 48(5) Clinical Chemistry 691-98 (May 1, 2002). Therefore, attempting to hold the number of errors that Little Critters has discovered to an arbitrary percentage error is inappropriate. Assessment of error requires assessment of the whole process for realistic evaluation.

F. Antech's Accuracy and Precision Fall Short of Acceptable Guidelines, Rendering Antech's Testing Services and Results Undependable

48. Little Critters' test results received from Antech have been reviewed by a boarded veterinary pathologist. The pathologist concluded from the documents that Antech does not appropriately address known technical errors in laboratory test results reported to Little Critters. Further, written communication between Antech professional staff/management and Little Critters was misleading. The pathologist further concluded that the laboratory test results received by Little Critters from Antech exceed the level of errors that could reasonably be expected to be confirmed by an individual clinician, that they are indicative of a significantly higher level of error, a level which is unacceptable in /////

the industry. The pathologist further concluded that Antech has changed results without following industry guidelines for documentation.

- 49. Beginning in December 2017, Little Critters began to have concerns about the quality of Antech's lab results. At that point, Little Critters had received results from Antech from fecal samples that came back negative and, when questioned, were changed by Antech to positive. Suspicious of the results received from Antech, and concerned about the potential impact on the practice resulting from incorrect diagnoses stemming from false lab results, Plaintiff Dr. Patt began watching more closely for errors in the results and found numerous ones. These errors included blood serology for disease testing (both false positives and false negatives), as well as blood chemistry results, urinalysis and fecal results.
- 50. It is not possible for Little Critters to rerun or check all of Antech's test results for the simple reason that they are a veterinary practice, not a veterinary diagnostic reference laboratory. Nevertheless, Little Critters found upon closer inspection that Antech's services and results were simply unacceptable from a veterinary perspective, far below what were accepted in their own in-house laboratory, what was provided in previous and recent experience with Antech's competitor, IDEXX, and what would be tolerated in a veterinary clinical laboratory.

1. <u>EHRLICIA CANIS, BORRELIA BURGDORFERI, ANAPLASMA, AND DIROFILARIA</u>

51. Further, there are specific conditions and tests for which Antech's unacceptably poor performance has been clearly established. *Ehrlichia Canis, Borrelia Burgdorferi* (Lyme Disease), *Anaplasma, and Dirofilaria* (heartworm) titers are screened by the Accuplex4 testing equipment, which is currently marketed by Antech and was marketed to Little Critters. Antech has claimed to

1 the veterinary community that *Ehrlichia Canis*, as measured by the Accuplex4, 2 should have diagnostic sensitivity approaching 100% based on original data 3 described in an article written by Moroff, an Antech employee, as lead author: 4 Moroff S, Sokolchik I, Woodring T, Woodruff C, Atkinson B, Lappin MR, *Use of* 5 an Automated System for Detection of Dog Serum Antibodies against Ehrlichia Canis Glycoprotein, 26(4) Journal of Veterinary Diagnostic Investigation, 558-62 6 7 (July 2014). In that piece, Moroff and his co-authors claim that the AccuPlex4x 8 features "earlier detection which makes the assay more sensitive" than competing 9 tests, including the 4DX offered by IDEXX. Antech repeated that contention 10 even though the paper was substandard, using a sample number of only 8 animals without a negative control population. See also Chandrashekar R, Mainville CA, 11 Beall MJ, et al. Performance of a Commercially Available In-Clinic ELISA for 12 13 [Kh1] the Detection of Antibodies against Ana-Plasma Phagocytophilum, Ehrlichia Canis, and Borrelia Burgdorferi and Dirofilaria Immitis Antigen in 14 15 *Dogs*, 71 Am J Vet Res 1443-1450 (2010). 16 52. A team of veterinary internal medicine specialists in the Northeast United States then investigated AccuPlex 4 and showed it had substandard 17 18 diagnostic sensitivity in comparison to other methods in the marketplace to test for Borrelia, Anaplasma, and Dirofilaria. Goldstein, RE, Beall MJ, and Alleman 19 AR, Performance Comparison Of SNAP® 4Dx® Plus And Accuplex® 4 for the 20 21 Detection of Antibodies to Borrelia Burgdorferi and Anaplasma 22 Phagocytophilum, 12(2) International Journal of Applied Research in Veterinary Medicine 1 May 2014). 23 24 ///// 25 ///// 26 ///// 27 ///// 28 /////

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

SNAP 4dx Plus vs AccuPlex 4 Test

Snap 4dx Plus

- Sens: 89-99%, Spec: 99%
- B. burgdorferi Sens: 98.5%, Spec: 95.7% Reproducibility 96%
- Only detects infection (C6)
- Sens: 91.7%, Spec: 88.7%
 - Sens: 97.1, Spec: 95.3% E. canis & E. ewingii^

- AccuPlex 4
- Heartworm Sens: 76%, Spec: 95%
- B. burgdorferi Sens: 78.5%, Spec: 72.9% Reproducibility 89% Vaccine and exposure*
- Sens: 75%, Spec: 82.6%
- Sens: ?, Spec: ? Only E. canis
- ^ More common in the central and south central U.S.
- * Possible issue with early infection & Lyme vaccinatio

Nevertheless, Antech continued to tout misleadingly to the veterinary community the false claim of the superiority of its Accuplex4 test over competitors.

- 53. Based on the known prevalence of disease in the surrounding Phoenix area, one would expect a minimum of 4% of dogs would be *Ehrlichia* positive, but this figure could well be as high as 15-20% depending on seasonal conditions. Using Accuplex4, Plaintiff Dr. Patt caused 30 dogs to be tested from January 2018 to present for *Ehrlichia Canis* (predominantly in the spring, the prime season for the condition) and all samples were reported by Antech as negative. She has confirmed 3 of these results as false negatives based on comparison to the IDEXX 4DX test, which is consistent with expected results given the sensitivity and specificity results depicted in the above figure.
- 54. For a dog named "S. Kukkola," Antech's Accuplex reported negative results for E. Canis even though the numbers on the test were greater than 1:2048, which should generate a positive result. The same then was rechecked with a verified result. Later the sample was submitted to the clinical laboratory at North Carolina State University at Dr. Patt's request for PCR testing, which confirmed the patient was infected with *Ehrlicia*. When, after being informed of these facts, Jim Church of Antech was asked if he trusted the Accuplex test, he said, "Well I

work for the company so it's difficult to say but what I will say is that I don't trust it today as much as I did yesterday."

2. <u>LITTLE CRITTERS' EXPERIENCE WITH FECALS</u>

- 55. Little Critters' experience with Antech testing of fecal samples provides further specific examples of inaccuracy and imprecision, rendering its testing results undependable. For example, a bearded dragon lizard presented with diarrhea on March 24, 2018. A fecal sample was collected in the standard container provided by Antech and provided for pick up by Antech. Little Critters received a final report from Antech stating a negative result, but that result did not fit the clinical presentation. Consequently, Little Critters requested verification from the laboratory. Little Critters' personnel were told the sample had leaked in transit but that Antech would try to verify it. Four days later Little Critters received a call from Antech stating that Antech was able to rerun the test, with no commentary about leaks, and that the result was actually positive for *Coccidia*. A fecal sample was repeated after April 11, 2018, subsequent to treatment with Ponazuril, and it was also reported as negative. The owner continued to report diarrhea and malodorous stool, making this result suspect.
- 56. Similarly, Antech provided a negative fecal test result for a dog named "Bella." After Little Critters requested a recheck, the test result came back positive for *Coccidia* and listed as a match. Sara Reed of Antech stated that it looked like the technician left the field that asks if the recheck matches blank and that Antech's information technology staff was looking into why doing that would cause the report to say that the results match when it was not entered that way. She apologized for the error and confusion.
- 57. Antech provided a negative fecal test result for a dog named "Honey." After Little Critters requested a recheck, the test result came back positive for *Giardia*, a potential human/zoonotic disease.

Antech provided a negative fecal test result for a dog named "Petal." 58. After Little Critters requested a recheck, the test result came back positive for Giardia and hookworms. Dr. Patt then communicated with Dr. Lewis of Antech, stating that these results made no sense. Dr. Lewis agreed with that statement. Dr. Patt then asked how these conditions were missed on the first report. Dr. Lewis stated he could not answer that question. Dr. Patt then told Dr. Lewis that she could not trust Antech's results. Jim Church of Antech admitted that Antech did not co-ordinate its efforts well in this case and could understand why the situation would be confusing and contradictory. Little Critters then sent a sample

59. A lizard named "Rigby" was suffering from diarrhea. Little Critters received a result from Antech negative for all parasites, which is unusual in lizards and particularly so when one is clinically ill with diarrhea. One week later, Antech contacted Little Critters to say the final result was incorrect and the fecal was actually positive for *Coccidia*. Then the same day, Little Critters received another call from Antech indicating the second result was incorrect and the fecal sample actually had two parasites: *Coccidia* and Pinworms.

from the patient to IDEXX, and the result was positive for *Giardia* only.

60. Antech provided a negative fecal test result for a reptile named "Tank." After Little Critters requested a recheck, Antech amended the test report to change it from Rhabditiform to Nyctotherus. A week later, the test result came back positive for Entamoeba 2+. Entamoeba has the potential to be a zoonotic disease.

3. <u>LITTLE CRITTERS' EXPERIENCE WITH COCCIDIODES TITERS</u>

61. Antech offers a test for *Coccidioidomycosis immitis* (Valley Fever), which is a potentially zoonotic diseases, commonly referred to as *Cocci*, with test results reported as titers. Little Critters' experience with this test also exemplifies

Antech's woefully substandard performance. For example, on a dog patient known as "Cinder," Little Critters requested a recheck of Antech's initial negative result. At first, Antech responded that there was insufficient sample to perform a recheck, but then an Antech employee named Andrea contacted Little Critters, saying that the recheck had verified the negative test result. Then Little Critters received a report from Antech showing that, upon a recheck, the sample was positive for *Cocci*. In communications with Little Critters about the incident, Antech's documentation identified "tech error" as the source of the problem, including a notation "see initials," that may well indicate that the technician in question was known for errors. When Little Critters pointed out this series of events to Antech, they were told that the Antech laboratory was not fully informed before calling Little Critters.

- 62. For a dog named "Squeeky," Antech first reported a positive test result for *Cocci* and then changed the result to negative with no notification to Little Critters. In response to Little Critters' inquiries, Antech sent an email establishing that this event represented a breakdown of protocol. A subsequent email established that the Antech technicians did not follow standard operating procedures. Then Antech sent a lab alert contending that the delay in reporting results was due to mechanical issues.
- 63. For a dog named "Butters," Antech provided a test result for *Cocci* that was a false positive.
- 64. For a dog known as "Cricket," Antech initially provided no result but instead claimed there was an insufficient sample to be tested. Then Antech sent a positive test result.
- 65. For a dog known as "Tawnie," Antech initially provided a positive test result for *Cocci* but later changed it to negative.

4. <u>LITTLE CRITTERS' EXPERIENCE WITH URINALYSIS, CBC TESTING, AND PATHOLOGY REVIEW</u>

- 66. Little Critters' experience with Antech with respect to urinalysis, CBC (Complete Blood Cell Count) testing, and pathology reviews also demonstrates that Antech's performance was substandard. For example, Antech reported that a rabbit named "Shadow" had urate crystals, which would not be possible in this sample of rabbit urine. Dr. Patt requested that this urine be rechecked. Two pathology reviews were required before getting accurate crystal identification, and the results were changed, but Antech's records still listed the test result as a match for urate crystals.
- 67. A dog named "Christmas" suffered from immune mediated hemolytic anemia. After Antech reported abnormal results, the patient had a transfusion, and subsequent immunosuppressive medications, resulting in blood morphology changes beyond the Antech technician's skill level, preventing Little Critters from being able to recheck the lab results. Accordingly, Little Critters requested a pathology review of this case, but Antech never provided one.
- 68. Antech performed what is known as a CBC test for a lizard named "Mr. Bittles." The test result indicated zero monocytes, zero basophilis, and zero eosinophils. In light of the patient's condition, Little Critters requested a pathologist review the blood slides to verify the results. Antech's pathology reviews for Mr. Bittles stated that the patient had monocytosis, but that conclusion did not match the reported initial results, which were not marked as preliminary.
- 69. Pathology reviews are supposed to be conducted by a board certified veterinary pathologist. In at least two cases, Antech's pathology reviews were conducted by a veterinarian who was not a veterinary pathologist. That situation is analogous to a medical general practitioner for a human patient purporting to do the work of a board-certified medical pathologist.

- 70. A rabbit named "Huxley" was scheduled for surgery. Antech reported that the patients platelets were low, which could be an issue for surgery due to bleeding. Little Critters requested verification, but Antech did not change the initial report. Rather, Antech sent the exact same report indicating low platelets, but confusingly changed only the match section of the report to indicate that this did not match the original results. Upon Little Critters' further request for clarification, Antech changed the report to indicate adequate platelets.
- 71. This fact pattern with "Huxley" was common. There were many examples where Little Critters requested verification of test results from Antech, but was sent back a report with the same results at the top of the page, but with the word "no" under the match heading at the bottom of the report to indicate that the recheck did not match the initial report. Such a slapdash method of responding would be easy for veterinarian offices to miss in a busy practice. Little Critters would have to request the correction again, and often more than once, until Antech sent a properly corrected report.

5. <u>LITTLE CRITTERS' EXPERIENCE WITH</u> <u>BIOCHEMICAL ANALYSIS</u>

72. Little Critters' experience with Antech's biochemistry tests provide further concrete examples that Antech's testing services were inaccurate, undependable, and imprecise. For example, a dog named "Cody" was a long-term patient of Little Critters. A specialist in a different clinic than Little Critters ordered a CBC/Chemistry test for Cody run by Antech and received a report of abnormally high GGT (gall bladder value) and triglyceride levels, which they shared with Little Critters. As a result of the false positive high GGT value, an internist at yet another clinic emergency abdominal ultrasound was conducted on the patient. Little Critters asked the specialist to have Antech to verify the results, at which point, Antech changed the results to a lower triglyceride level and

- 73. For a lizard named "Lizzy," Antech's original test results indicated an abnormally low Potassium level of 0.9 and a uric acid level of 0.0. That uric acid level made no clinical sense. Little Critters requested a recheck, upon which Antech amended the uric acid level to <1.5 mg/dl. Jim Church of Antech admitted that the results did not make clinical sense.
- 74. For a cat named "Leonardo," Antech reported a Magnesium (Mg) of 5.3. Little Critters consulted with an internist to determine the possible causes of such an anomalous result. Then Antech reported the result was an error and the level was actually normal. As Antech acknowledged in an email, "We probably could have caught this . . . "

6. <u>LITTLE CRITTERS' EXPERIENCE WITH RESPIRATORY FASTPANEL PCR</u>

- 75. Little Critters' experience with Antech's respiratory fastpanel PCR tests provides further demonstration that Antech's performance was unacceptable.
- 76. The influenza virus tested for by the fastpanel PCR test mutates frequently. One of the most prevalent strains is H3N2, but Antech's assay through at least August, 2019, does not test for it and thus cannot detect it. Consequently, Antech's influenza test consistently generates false negatives for patients infected with H3N2.
- 77. For example, for a dog named "Mouse," Antech reported a positive test result in 2019 for *Mycoplasma*, even though the patient showed no signs or symptoms. From a sample drawn at the same time as the one Antech analyzed, IDEXX reported a negative result and verified it. This sample was provided from a non-symptomatic animal as a test of the accuracy of the services provided by Antech and IDEXX.

- 78. For a dog named "Isabella," Little Critters provided a sample to
 Antech of a non-symptomatic patient. Antech reported a positive test result for
 Mycoplasma, but the patient showed no symptoms, including no coughing, and
 has no history of recent vaccination, making the positive result almost certainly
 false. IDEXX tested a sample drawn at the same time for this patient and
 reported a negative test result for Mycoplasma.
 - 79. In short, two asymptomatic dogs were assessed by Little Critters using Antech's canine respiratory PCR Panel and both results were false positives for *Mycoplasma*, which creates doubt as to whether Antech's *Mycoplasma* test is trustworthy.
 - 80. For a dog named "Fancy," Antech reported the patient positive for *Bordetella*. Those results could not be verified because Antech stated that they had discarded the sample IDEXX reported a respiratory panel as negative. IDEXX was then asked to, and did in fact, verify the negative results as accurate. The patient's lack of response to the typical medication used to treat *Bordetella* fit with a negative result. The patient then tested positive for *Cocci* at IDEXX. Had the *Bordetella* diagnosis been accepted, testing and treatment for the true condition, *Cocci*, would have been delayed.

7. <u>LITTLE CRITTERS' EXPERIENCE WITH LYME</u> ACCUPLEX

81. For a dog named Whiskey, Antech provided a false positive test result for Lyme Disease. The Arizona puppy had no history of travel outside of the state and thus was unlikely to encounter Lyme. A follow-up test with 4DX, a competitive test to Antech's, came back negative.

/////

8. <u>LITTLE CRITTERS' CUSTOMER SERVICE</u> EXPERIENCE

- 82. Antech also failed to provide acceptable customer service. For example, with a cat named "Butterscotch," Little Critters called Antech to cancel an initial test, which was drawn again and sent the next day, in an effort to determine the appropriate timing for a cesarean section on a cat. But Antech never cancelled the first test. When Little Critters called Antech for the results of the second day's test, they were given the results from day one.
- 83. For the dog named "Isabella," Sara Reed of Antech admitted that the treatment of testing for the patient was a breakdown of normal protocol. First Antech contended that the problem was with its equipment for detecting *Cocci*, but the technician did not flag the system. Antech did not notify Little Critters of what was happening. Antech admitted that no results should have been released until the recheck was verified. Sara Reed stated that Antech's verification was sent to its North Carolina laboratory, which indicated Isabella was positive, but then said that Antech does not have PCR testing in North Carolina and that the patient was negative on the FastPanel PCR test. Antech admitted they had performed the verification themselves, and then later changed the report to read, "Reviewed by technician."
- 84. For the dog named "Christmas," Antech stated that the pathology review was pending, but it was never received, and the report was changed to reviewed by technician.
- 85. For a bird named "Charlie," after two or three other excuses, Antech admitted that the entire sample was consumed in multiple "machine failures" and requested a new sample, but unfortunately the bird died while awaiting results.
- 86. Antech repeatedly failed to pick up laboratory samples, or the Antech driver would come before the scheduled pick-up time and leave without picking up samples put in the collection box before the scheduled time but after

the driver appeared. This failure was particularly egregious when Little Critters were trying to establish progesterone levels for impending cesarean section deliveries, which are obviously a time-sensitive matter.

- --

9. <u>ALTERING MEDICAL RECORDS</u>

- 87. Veterinarians are obligated by state licensing authorities and good practice to maintain accurate medical records. Doing so is important because, among other reasons, they and others may need to look at patient files to determine what happened to a patient over a course of time.
- 88. Accordingly, standard practice is to not alter the record of any test result. Rather, if a second test is conducted, it should be clearly labeled as such. If it turns out an initial test result is incorrect, it is typically "amended," such that the original result is still evident in the file as well as the amended, corrected result. Alternatively, certain test results are marked as "preliminary," when appropriate, and then marked as "final," when everything has been resolved, but again, both results are in the file.
- 89. Antech's testing services frequently interfaces with veterinary practice management software, which maintains the patient's medical record, via the Antech "Dashboard." In those circumstances, the veterinary practice uses the Dashboard as its record of doctor requested test results as conducted and reported by Antech.
- 90. Antech sometimes provides information correcting erroneous initial test results by "updating" the test result via the Antech Dashboard. This process results in a medical record containing the initial test result to be changed **without** an appropriate laboratory notation such as "addendum" or "corrected," the required process that would also leave the initial test result record accessible. In practice, Antech's "updating" approach leaves practitioners unable to check Antech's error rate. More fundamentally, it puts veterinarians at risk of failing to

abide by licensing board dictates that they maintain accurate medical records or to comply with prevailing guidelines of veterinary care.

- 91. To state the problem differently, if a veterinarian communicates the first test result from Antech to clients and that result is later changed by Antech without clear demarcation, the veterinarian has no record proving that her statements to the client were true at the time of her client communication. The veterinarian is legally responsible to document all findings that lead to diagnoses. These unannounced changes to test results by Antech thus place her license in jeopardy.
- 92. To be clear, Antech's pattern on these issues was inconsistent. In some instances, Antech would change the test record without any amendment. In others, the report was amended, but the initial incorrect results were kept intact. In a few instances, Antech amended the test report in the appropriate manner.
- 93. For example, for the lizard named "Rigby," Antech changed the test result from negative to positive by "updating" it via telecommunications. That approach means Little Critters would no longer have any record of the original document reflecting the initial test results in the electronic medical records it references for Antech tests. Because Dr. Patt was concerned about continually changing test results from Antech, however, she had printed the original report that documents this medical record alteration without flagging of the change. Similarly, Antech changed the initial test results via "updating" for the patients "Christmas" and "Squeeky," whose conditions were relayed above, without correct demarcation. Numerous reports for other patients also indicate they were "updated," leaving Little Critters with no record of the initial test or result for patients named "Polly," "Bovi," "Hunter," and two patients named "Casey." In the case of Bovi, Antech sent a final report on one day listing E. Canis serology as a strong negative while the next day Antech sent another report denominated final listing the result as positive.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

10. THE EXPERIENCE OF OTHER VETERINARIANS

- 94. Dr. Patt posted her concerns about Antech's false lab reports on an online forum for veterinarians, to which other veterinarians around the country responded with numerous additional examples of Antech providing false lab results. Other veterinarians have included among their experiences with inadequate Antech laboratory test results, the following:
 - (a) Falsely reporting sensitivities to antibiotics that violate FARAD with regard to chicken cultures;
 - (b) Lost two histopathology samples where the vet had sent the entire masses, so there was no way to go back for more tissue;
 - (c) Incorrect reports sent on two cases where the vet contacted the pet owners with the results only to have Antech send "corrected" results later, which required the vet to call the owners to tell them that he had provided them with incorrect lab results;
 - (d) UAs sent out for analysis did not come close to what vet saw in house; samples loaded with bacteria, WBC, even sperm, and Antech saw "no cells and no bacteria;"
 - (e) Found their T4 levels on cats were very unreliable when a cat came back normal and when rechecked two weeks later (after he continued to lose weight and vomit), he was severely hyperthyroid; checked the other T4 results that had been relied on and found two others that were hyperthyroid;
 - (f) Wrong sample used for a black lab with a large, black mass on its toe; the results from Antech reported malignant melanoma, so the entire toe was amputated and sent to Antech and the histopathology report came back squamous cell carcinoma; when asked why the results did not include the melanoma or the decalcified toe bone, the

- tech reported that they were not present in the sample, demonstrating that Antech provided results from the wrong sample;
- (g) After Antech bought one local lab and merged it into Antech, a veterinarian sent a UA to get an ID on a Crystal seen in urine; on a fresh sample, there were at lease 30 crystals per HPF; Antech's results were completely off-base, showing no crystals, the pH, SP GRAV and the blood were all completely different than the urine sent in; spoke with the person in charge and learned that the person handling the urine samples was running behind, so he would run about every tenth one, and then (slightly) adjust those results and report them for the other nine.

11. <u>ANTECH UNDERINVESTS IN LABORATORY PERSONNEL</u>

- 95. When Dr. Patt has been able to get an explanation from Antech as to why its test results were erroneous, one common explanation given is that the laboratory technician read the results incorrectly. This is not always an accurate statement of the incorrect reasons for the test result. It is, however, a result of the fact that Antech's laboratory technician positions are lowly paid, often working at night, and poorly managed, all in a manner that fails to meet the requirements for quality assurance in a veterinary diagnostic reference laboratory.
- 96. Antech laboratory technicians made the following comments about their employment on the website Glassdoor.com:
 - (a) Poor hourly wage and no work/life balance.
 - (b) Over worked under paid better off working at Walmart.
 - (c) Worst place I have ever worked in my life.
 - (d) There is a high turnover rate. I attribute this to a low pay and unrewarding work environment.

- (e) Under minimum wage cause of zoning loophole, not worth working here the pay is terrible for the amount of work expected from you. Especially for an overnight position and quota based job performance.
- (f) You make a dollar more than minimum wage that it.
- 97. Antech laboratory technicians made the following comments about their positions on the website Indeed.com:
 - (a) This is a terrible place to work. No work-life balance, terrible management/HR, low pay, and overall abusive work culture.
 - (b) Pay was less than I hoped for after two raises and promotions. I ultimately decided to move on with my career in search of greater challenges and better pay.
 - (c) Poorly trained management and expected to know everything without proper training beforehand and you never get out on time.OT is an expectation instead of an option.
- 98. In short, Antech has engaged in a variety of conduct designed to cut its labor costs as low as possible, below the level that would allow it to provide the level of professionalism and accuracy it promises in the Exclusive Agreement and Antech marketing materials.

12. ANTECH'S TESTING SERVICES AND RESULTS ARE UNACCEPTABLY INACCURATE, UNDEPENDABLE, AND IMPRECISE

99. All of the above indicates that Antech's services and test results are not reliably accurate. Nor are its laboratories "state-of-the-art." Nor does it "provide services in a professional manner by qualified personnel." Little Critters used IDEXX as a veterinary diagnostic reference laboratory both before entering into the Agreement and more recently. In its experience, the IDEXX services and results were substantially more accurate, dependable and precise than those

6 7

9

8

11 12

10

13 14

15 16

17

18

19

20 21

23

22

24 25

26 27 28

provided by Antech. Similarly, veterinary practices that have used competitors of Antech other than IDEXX have enjoyed services and results were substantially more accurate, dependable and precise than those provided by Antech.

ANTECH'S CONDUCT HARMS VETERINARY PRACTICES 13.

- 100. Antech's deficiencies have not improved over time but appear to have worsened. Little Critters has used Antech for a very small sample of tests in 2019, and all of those test results proved erroneous.
- 101. Antech's faulty laboratory practices threaten not only the health of animals, but of humans. For example, as alleged above, Antech provided false negative fecal results for hookworms in veterinary patients, such as in the instance of a dog named "Petal." Hookworms are a zoonotic disease infecting humans, and specifically children. Consequently, false negative results for this condition increase the likelihood that human children will contract hookworm from their pets. Ocular hookworm infections in children are known to often be confused with retinoblastoma, a type of childhood cancer requiring removal of the eye.
- As another example, Antech has provided false negative results for 102. Giardia in veterinary patients, such as in the instance of the dog named "Honey," as alleged above. Giardia is a zoonotic disease that humans can contract from dogs, which will increase the risk that the human will contract subsequent infections. Consequently, false negative results for this condition increases the likelihood that human will contract Giardia.
- 103. By providing invalid results to veterinarians across the country, Antech is also, in effect, proving invalid results to pet owners. As a result, pet owners lost pets needlessly and had to experience their pets suffering prolonged treatment, with concomitant psychic and economic costs, resulting from Antech's poor quality laboratory practices.

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

- As alleged below, Antech's practices have inflicted economic harm upon veterinarians, but they have also put veterinarians in an unacceptable position. Veterinarians swear an oath to behave in an ethical manner and provide care to patients with that requirement foremost in mind. State licensing boards hold the veterinarian, not the veterinary testing company, ultimately responsible for the care of patients. Accordingly, once Little Critters learned of the numerous deficiencies in Antech's services, it became difficult to know which Antech test results to trust. In short, this case is an attempt to vindicate the ability of veterinarians to provide the best care possible to their patients.
- 105. Antech's executives have displayed a practice of covering up deficiencies in Antech's laboratory testing operations rather than admitting fundamental problems and ameliorating them. Many incidents demonstrate these cover ups, but two are illustrative.
- The first concerns the rabbit named "Shadow." The laboratory test result indicated that Shadow had "Amorphous Urate Crystals" of >50 but a blood pH of 8. As a matter of simple chemistry, such a result is impossible, since crystals cannot form in a basic solution, such as indicated by a pH in excess of 7. Dr. Patt told a technician at Antech that rabbits do not get urate crystals, but the technician responded first that these were indeed urates and later that there were insufficient samples to recheck. Then Dr. Lon Rich, a highly experienced and high-ranking veterinary pathologist for Antech, got involved and stated that the urates might be due to medications the rabbit had ingested, without confronting the fact, which he obviously knew, that urates would not form in an animal with a basic urine. In other words, he was covering up an obvious deficiency in Antech's test results by reaching for implausible explanations to defend those results.
- The second concerns the lizard named "Lizzy." As alleged above, Antech's test result indicated that she had uric acid of 0 and a Potassium level of

0.9. Dr. Patt conveyed to Antech that those test results were ludicrous and that Antech would not report such results if it kept track of a minimum-maximum range of real world results. In particular, any lizard of that species with a Potassium level below 1.5 would die of heart failure. Antech should never have reported the results to Dr. Patt in the first place as they should know that such absurd results indicate a problem with the test rather than the patient's condition. At that point, Dave Lewis of Antech became involved. Dave Lewis is a highly-credentialed and high-ranking pathologist within Antech. But he never addressed the Potassium level reading because it was indefensible. In other words, he too was covering up an obvious deficiency in Antech's test results.

What likely happened is that Antech committed an aspiration error, failing to suck up enough of the sample due to clotting. That would explain the absurdly low results. In that instance, a veterinary diagnostic reference laboratory should, according to industry custom and practice, tell the veterinarian to resubmit, run a second test at no charge, and confirm the result. Instead, in this instance, Antech reverified its results rather than admitting to deficiencies in their operations.

CLASS ALLEGATIONS

108. Little Critters bring this action on behalf of themselves and the members of the proposed Class under Rule 23(a), (b)(2), (b)(3), and/or (c)(4) of the Federal Rules of Civil Procedure. The proposed Class consists of the following:

All veterinarians and/or their associated practice entities that are parties to an Exclusive Laboratory Services Agreement with Antech or have been such parties at any time since four years prior to September 19, 2018.

109. Excluded from the Class are Antech, its parents, subsidiaries, affiliates, officers and directors, any entity in which Antech has a controlling

interest, and all judges assigned to hear any aspect of this litigation, as well as their immediate family members.

- 110. <u>Numerosity.</u> Fed. R. Civ. P. 23(a)(1). The members of the Class are so numerous that joinder is impractical. The Class consists of around 4,000 members. The precise number is within Antech's knowledge and can be ascertained only by resort to Antech's records.
- 111. <u>Commonality</u>. Fed. R. Civ. P. 23(a)(2) and (b)(3). There are numerous questions of law and fact common to the Class that predominate over any questions affecting only individual members of the Class. Among the questions of law and fact common to the Class are:
 - (a) Whether Antech concealed the significant amount of false lab results that it was providing;
 - (b) What guidelines apply to determine whether Antech provided sufficient accuracy, dependability, and precision in its tests, services, and results;
 - (c) Whether Antech has provided a level of accuracy, dependability, and precision below applicable guidelines;
 - (d) Whether Antech's conduct puts veterinarians in an excruciating dilemma, forcing them to choose between continuing their contract and their duty to their clients, patients, oath and license once the veterinarian has lost trust in Antech's test results;
 - (e) Whether Antech took steps to make it more difficult for veterinarians to learn of Antech's practices, as alleged above;
 - (f) Whether Antech used the economic threat of litigation, rather than the merits of litigation, to coerce veterinarians to remain in contractual relations with Antech;
 - (g) Whether Antech is placing public health at risk;
 - (h) Whether Antech is violating the public trust;

- (i) Whether Class members are entitled to restitution, and in what amount;
- (j) Whether Antech violated its duty of good faith and fair dealing under the Exclusive Agreements; and
- (k) Whether Class Members are entitled to damages and a declaration of relief as a result of Antech's breach.
- 112. <u>Typicality.</u> Fed. R. Civ. P. 23(a)(3). Little Critters' claims are typical of the claims of the members of the Class and, like all members of the Class, Little Critters entered into an Exclusive Agreement with Antech. Little Critters have no interests antagonistic to the interests of any other member of the Class.
- 113. Adequacy. Fed. R. Civ. P. 23(a)(4). Little Critters are each a representative who will fairly and adequately assert and protect the interests of the Class and have retained counsel experienced in prosecuting class actions. Accordingly, each Plaintiff is an adequate representative, who will fairly protect the interests of the Class.
- 114. Superiority of Class Action. Fed. R. Civ. P. 23(b)(3). A class action is superior to all other available methods for the fair and efficient adjudication of this lawsuit, because individual litigation of the claims of all members of the Class is economically unfeasible and procedurally impracticable. While the aggregate damages sustained by the Class are in the millions of dollars, the individual damages incurred by each member of the Class resulting from Antech's wrongful conduct are relatively small to warrant the expense of individual lawsuits all the more so in light of likely reprisal by Antech in the form of meritless counterclaims for breach of the Exclusive Agreement and the confidentiality clauses therein. The likelihood of individual Class members prosecuting their own separate claims is thus remote, and, even if every member

of the Class could afford individual litigation, the court system would be unduly burdened by individual litigation of such cases.

- 115. The prosecution of separate actions by members of the Class would create a risk of establishing inconsistent rulings or incompatible standards of conduct for Antech. Additionally, individual actions may be dispositive of the interests of the Class, although certain class members are not parties to such actions.
- 116. <u>Injunctive and Declaratory Relief.</u> Fed. R. Civ. P. 23(b)(2). The conduct of Antech is generally applicable to the Class as a whole and Little Critters seek equitable remedies with respect to the Class as a whole. Little Critters do not seek monetary relief as an aspect of the Rule 23(b)(2) class. As such, the systematic policies and practices of Antech make declaratory or equitable relief with respect to the Class as a whole appropriate.
- 117. <u>Issue Certification</u>. Fed. R. Civ. P. 23(c)(4). In the alternative, the common questions of law and fact, set forth above, predominate and are appropriate for issue certification on behalf of the proposed Class.

COUNTS

COUNT I

Unlawful Business Practices

(California Business & Professions Code § 17200, et seq.)

- 118. Little Critters incorporate and reallege by reference each and every allegation above as if fully set forth herein.
- 119. A business act or practice is "unlawful" under the UCL if it violates any other law or regulation.
 - 120. Federal law, 15 U.S.C. § 2, prohibits attempted monopolization.

26 /////

23

24

25

27 | | /////

28 /////

G. THERE IS A DISTINCT MARKET FOR VETERINARY DIAGNOSTICE REFERENCE LABORATORY TESTING SERVICES IN THE UNITED STATES

- 121. Veterinary diagnostic reference laboratory testing services constitutes the relevant product market in this case. Such services include the tests, test results, support services provided by the seller, and all physical items used in connection with those things, such as specimen collection containers. Veterinarians have no reasonable substitute for such testing services, and such testing services are a vital part of their veterinary practices.
- 122. Other diagnostic testing services are not reasonable substitutes for veterinary diagnostic reference laboratory testing services because they do not cover the same type of tests as those provided by veterinary diagnostic reference laboratory testing services or because they are not available to veterinarians operating a veterinary practice.
- 123. Historically, the price of veterinary diagnostic reference laboratory testing services has been completely independent of the price of other types of diagnostic testing services.
- 124. The veterinary field has long recognized that veterinary diagnostic reference laboratory testing services are a distinct part of the profession, discussing and analyzing such services without reference to any other type of diagnostic testing.
- 125. "Elasticity" is the term used to describe the sensitivity of the amount demanded of a product to a change in the price charged for it. The more sales of a certain product would decline as the price of that product increases, the more elastic are the prices of that product. Conversely, inelastic pricing exists when the amounts sold of a certain product do not decline significantly even when the price of that product increases significantly. In other words, when customers have few or no practical alternatives to a given product in the form of cheaper products of

- 126. Pricing for veterinary diagnostic reference laboratory testing services is highly inelastic, in large part because there are no adequate substitutes for those services.
- Those in the market for veterinary diagnostic reference laboratory testing services, both sellers and veterinarians, recognize that it constitutes a distinct market. Further, both sellers and veterinarians recognize that veterinarians need access to a wide array of diagnostic tests available only from veterinary diagnostic reference laboratories. Indeed, veterinarians cannot always know what the needs will be of the next patient that walks in the door. Consequently, veterinarians need to know they can go to a seller of veterinary diagnostic reference laboratory services and obtain the test they need rather than trying to chase down a distinct seller of just the specific test the veterinarian needs at the moment. As a result, the market has developed such that providers of veterinary diagnostic reference laboratory testing services sell a full array of diagnostic tests. Virtually no sellers exist who sell just the testing services, including results, for a single diagnostic test, but not others. Therefore, veterinarians view sellers of veterinary diagnostic reference laboratory testing services from the perspective that such sellers will be able to conduct any test typically handled by veterinary diagnostic reference laboratories to help veterinarians provide care to their patients. Accordingly, considering all the various tests offered by veterinary diagnostic reference laboratories to be part of a single distinct market reflects the commercial realities of veterinary practice.
- 128. The geographic boundaries of the market for selling veterinary diagnostic reference laboratory testing services are those of the United States. Because veterinarians are licensed to practice by state authorities, they would be understandably reluctant to have samples tested by laboratories located outside of

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

the United States, in part because state authorities might be dubious of such a practice and because the veterinarians themselves would naturally be less confident of the services provided in another country with which the veterinarian is unfamiliar on a professional basis. Further, shipping veterinary specimens across international borders would be considerably more expensive than shipping them within the United States, partly because such specimens would be subject to customs inspections. Nor would custom authorities handle lightly the shipping of possibly diseased samples into their country. Historically, virtually no veterinary practices located within the United States obtain veterinary diagnostic reference laboratory services from outside the United States. Conversely, specimens collected by veterinarians within the United States are frequently transported across state lines and might be tested at a facility located within another state, regardless of region, for logistical reasons.

H. ANTECH HOLDS SUBSTANTIAL MARKET POWER IN THE MARKET FOR VETERINARY DIAGNOSTIC REFERENCE LABORATORY TESTING SERVICES IN THE UNITED STATES

- 129. Approximately 90% of the sales of veterinary diagnostic reference laboratory testing services in the United States are sold in roughly equal proportions by either Antech or IDEXX. In other words, each of Antech and IDEXX accounts for roughly 45% of the share of that market. The remaining 10% is split among entities, with the two largest being independents known as Phoenix and Marshfield, and the remainder accounted for by ARP/ZNLabs, ETHOS, National Biovet and a handful of other quite small regional laboratories. The market share of these sellers other than Antech and IDEXX has not grown collectively in memory, but is instead shrinking collectively over time.
- 130. Mars, the parent company of Antech, owns more veterinary hospitals than any other entity in the United States. Mars requires such facilities to use

Antech exclusively for diagnostic laboratory tests, further insulating Antech from competitive pressure from those potential customers of other sellers in the market.

- 131. Years ago, there were numerous veterinary lab diagnostic services. Over time, they have consolidated. Much of the consolidation has resulted from Antech's purchase of competing services. By 2015, there were only three major competitors in the: IDEXX, Antech and Abaxis. Antech purchased the Abaxis Veterinary Reference Laboratory, leaving only the two major competitors in the market.
- 132. High barriers to entry have prevented new entrants into the market for the sale of veterinary diagnostic reference laboratory testing services in the United States. Entry into the market involves significant start-up capital expenditures. A new entrant would have to incur tens of millions of dollars in costs, including capital expenditures on large laboratory facilities, testing equipment, and obtaining local land use approvals for the construction of new laboratories handling diseased samples. Some of the equipment used to test animal samples is developing rapidly and thus could well be obsolete by the time the hypothetical new entrant is actually ready to open business. The investment in facilities and testing equipment is sunk in that the capital has little to no alternative value.
- 133. The barriers to entering the market are also strengthened by the difficulty of staffing a new company that would attempt to compete robustly with Antech and IDEXX. Staffing such a company would require a large, skilled workforce of veterinarians, veterinary pathologists, veterinary assistants, technicians, and those experienced in managing them. The veterinary field is sufficiently specialized that it would not be possible to hire such an extensive skilled labor force without bidding up labor costs substantially over current levels. Even convincing enough such workers to relocate to new facilities would be a difficult and expensive proposition.

The misconduct alleged herein constitutes another barrier to entering the market. The Exclusive Arrangements with Antech mean that the 45% of buyers in the market could not rapidly transition to a new entrant. Further, IDEXX also uses long-term exclusive contracts similar to Antech's with the veterinarians IDEXX serves, foreclosing another 45% of the market to potential new entrant. Any investors in a hypothetical major new entrant to the market would be dissuaded from investing by the inordinately risky prospect of investing tens of millions of dollars to compete in the market with 90% of the potential customers foreclosed from patronizing the new entrant until their years long exclusive contracts terminated.

- 134. The onerous terms Antech imposes in its Exclusive Agreements both demonstrate its market power and enhance it. A veterinary diagnostic reference laboratory in a fully competitive market would not be able to impose such onerous terms on purchasers. Instead, they would choose a competitive alternative with more favorable terms, pressuring the veterinary diagnostic reference laboratory to shift away from onerous terms to less onerous ones to survive in the marketplace. Further, the onerous terms Antech imposes act to shield it from competitive pressures by making it virtually impossible for veterinarians to switch the bulk of their purchases to one of Antech's competitors during the term of their Exclusive Agreements with Antech.
- 135. Antech adopted a policy long ago of steering veterinary customers to exclusive dealing contracts by offering pricing in those contracts that is substantially less supracompetitive than the pricing offered outside those contracts and by offering service under those contracts that is supposed to be more responsive than that offered outside those contracts. Antech has and currently instructs and supervises its sales personnel to drive veterinarian customers into the Exclusive Agreements, with overwhelming success, a success mirrored at IDEXX. None of the veterinarians in the class, nor Little Critters, was a party to

the original Exclusive Agreements Antech initially offered. Little Critters is not challenging those Exclusive Agreements because of some shift in the economic winds, but because the anticompetitive nature of those contracts was revealed to Little Critters when it learned, to its dismay, that Antech's service under those contracts is woefully substandard.

- Antech and is not subject to negotiation with veterinarians. Certain terms affecting overall price are subject to negotiation within a relatively narrow range, but the negotiation primarily takes the form of Antech offering slightly better price terms, discounts, and amount of "loan," in return for a promise by the veterinarian to meet increased minimum purchase requirements. Antech has far greater bargaining power than any individual veterinarian it negotiates with, both because of its market power and because of the other imbalance of economic resources between Antech and individual veterinarians. Consequently, the terms of the Exclusive Agreements are greatly to Antech's liking, but accepted by veterinarians only because their choices are greatly constrained by both Antech's market power and IDEXX's decision to engage in highly similar conduct with respect to steering veterinary customers into onerous exclusive agreements.
- 137. As alleged above, the Exclusive Agreements contain numerous onerous provisions. In particular:
 - (a) Antech's requirement of a term of between 5 and 7 years in the Exclusive Agreements;
 - (b) Antech's requirement of an "evergreen provision" under which the Exclusive Agreement renews unless a veterinarian provides written notice a year before the end of the term and Antech's practice of making it as difficult as possible for veterinarian to comply with the notice requirement;

- (c) Antech's practice of providing a "loan" at the outset of the agreement whose balance is due only if the Exclusive Agreement is terminated, or if minimum purchase levels are not met;
- (d) Antech's position that, if the veterinarian terminates the contract, Antech is entitled to all its expected revenue under the terms of the contract, which Antech falsely contends constitute lost profits;
- (e) Antech's confidentiality provisions, making it more difficult for veterinarians to learn about Antech's conduct, particularly before they sign the Exclusive Agreement;
- (f) Antech's practice of suing veterinarians who seek to terminate the Exclusive Agreement, not out of a good faith belief in the merits of the litigation, but in order to impose prohibitive litigation costs *in terrorem*;
- 138. Through the Exclusive Agreements, Antech forecloses around 45% of purchasers in the market for veterinary diagnostic reference laboratory testing services. In other words, Antech's competitors cannot solicit effectively the business of the around 45% of prospective purchasers who would otherwise be available to them because those prospective purchasers would be in breach of the Exclusive Agreements if they bought substantial amounts from those competitors of Antech.
- 139. Antech's Exclusive Agreements have harmed competition in the market for veterinary diagnostic reference laboratory testing services. Because the Exclusive Agreements foreclose such a large portion of the market from effective competition, competitive forces have been reduced and competitive discipline on sellers in the relevant market has been weakened. As a result prices, for veterinary diagnostic reference laboratory testing services are higher than would otherwise be the case. In other words, Antech's Exclusive Agreements generate supracompetitive prices in the market. Further, and predictably, the detriment Antech's Exclusive Agreements inflict upon competition in the relevant

market also degrade the quality of veterinary diagnostic reference laboratory testing services relative to what would pertain if that market were truly competitive. Those insulated from competition typically raise prices and/or reduce quality relative to those operating in a fully competitive market, and that general rule applies to Antech here.

140. Increasing these harms to competition is that fact that IDEXX also steers its veterinary customers into onerous exclusive agreements. Because IDEXX also has a market share of roughly 45%, in addition to Antech's market share, approximately 90% of the market is foreclosed from effective competition. This foreclosure greatly increases barriers to entering the market to the point that no rational business would decide to undertake the investment necessary to enter into the business of selling veterinary diagnostic reference laboratory testing services to compete robustly with Antech and IDEXX when 90% of the potential customers would not be available for years after entry at best.

The Exclusive Agreements provide no real competitive benefits to the market. The purported procompetitive justifications for exclusive dealing contracts are almost always related to vertical chains of distribution in which a manufacturer (or analogous source) enters into exclusive dealing arrangements with dealers.³ These purported justifications assert that imposing exclusive sources of supply on dealers compels their loyalty to the manufacturer (or analogous source), preventing dealer free-riding and incentivizing dealers to invest greater amounts in promoting the manufacturer's (or analogous source's) goods or services. But here, Antech's and IDEXX's exclusive contracts are not made with dealers, but with the purchasers in the market: the veterinarians

27

28

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

²⁶

³ See, e.g., B. Klein & A. Lerner Procompetitive Justifications for Exclusive Dealing: Preventing Free-Riding and Creating Undivided Dealer Loyalty, Dept. of Justice, Antitrust Div. (2006) available at https://www.justice.gov/atr/procompetitive-justifications-exclusive-dealing-preventing-free-riding-and-creating-undivided

6 7

5

8

9 10

11

12 13

14 15

16

17

18

19 20

21

22

23

24 25

26 27

28

themselves. Of course, veterinarians are not in a position to free-ride on Antech's or IDEXX's efforts because they have to pay Antech or IDEXX for services. Indeed, they have to pay supracompetitive amounts for, at least in Antech's situation, substandard services.

ANTECH HAS ATTEMPTED TO MONOPOLIZE THE I. RELEVANT MARKET

- 142. In imposing the Exclusive Agreements and their onerous terms in these circumstances, Antech has attempted to monopolize the market for veterinary diagnostic reference laboratories.
- 143. Antech has also engaged in other conduct to further its purpose of attempting to monopolize the market. As alleged above, it has acquired competitors in the market, such as Abaxis, to increase Antech's market share and market power.
- 144. Also as alleged above, Mars is the parent company of Antech and owns more veterinary hospitals than any other entity in the United States. Antech has participated in Mars requiring that such facilities use Antech exclusively for veterinarian diagnostic reference laboratory tests, further increasing Antech's share of the market and power within that market.
- 145. Further, as alleged above, Antech engages in practices to prevent veterinarians from communicating about the nature of the Exclusive Agreements and the deficiencies in Antech's testing services. Antech also files and threatens lawsuits for in terrorem effect, intentionally seeking the entire stream of lost revenue damages as contractual damages for lost profits in order to dissuade veterinarians from terminating their Exclusive Agreements.
- 146. Because of its market power, this course of conduct presents a dangerous probability that Antech will monopolize the market for veterinarian diagnostic reference laboratory testing services.

4 5

6

7

8

10

9

12

13

11

14 15

16

17

18

19 20

21

22 23

24

25

26

27 28

Further, Antech undertook this conduct with the specific intent to destroy competition in the market for veterinarian diagnostic reference laboratory tests and thus monopolize that market.

ANTECH'S CONDUCT INFLICTED ANTITRUST INJURY ON LITTLE CRITTERS AND THE CLASS IN J. INTERSTATE COMMERCE

- Antech's sales to Little Critters and the Class occur in interstate commerce. For example, Antech is located in this judicial district, but sells veterinarian diagnostic reference laboratory testing services to Little Critters in Arizona. Further, Antech will test samples provided by Little Critters and the Class in its laboratories located throughout the United States.
- 149. Little Critters and the Class have suffered antitrust injury as a result of Antech's conduct. As alleged above, Antech's use of Exclusive Agreements with onerous terms, plus the other conduct it undertook in its attempt to monopolize the relevant market, have restrained competition, heightened barriers to entering the market, and insulated itself from competitive discipline. As a result, Antech charges supracompetitive prices and provides woefully substandard services. In a fully competitive market, Antech's substandard quality would lead to veterinarians quickly shifting their business to Antech's competitors. Due to Antech's anticompetitive behavior, however, veterinarians locked into Exclusive Agreements with Antech face no viable option for replacing Antech as their supplier of veterinarian diagnostic reference laboratory testing services until, at the earliest, the end of the term of their Agreement, assuming they do not run afoul of Antech's evergreen contract tactics. Consequently, those veterinarians suffer the plight of paying supracompetitive prices for substandard quality, exactly the fate the antitrust laws were designed to prevent.
- Pursuant to the Exclusive Agreements with Antech, Little Critters and the Class paid money to Antech. Little Critters request that this Court cause

Antech to restore this money paid by Little Critters and all Class Members and to enjoin Antech from continuing to violate the UCL as discussed herein or from violating the UCL in the future. Otherwise, Little Critters, the respective Class they seek to represent, and members of the general public may be irreparably harmed or denied an effective and complete remedy if such an order is not granted.

151. Plaintiffs are entitled to an award of costs and attorneys' fees pursuant to California Code of Civil Procedure, section 1021.5 and Civil Code, section 1717.

COUNT II Attempted Monopolization (Sherman Act § 2)

- 152. Little Critters incorporate and reallege by reference each and every allegation above as if fully set forth herein.
- 153. Section 2 of the Sherman Act (15 U.S.C. § 2) prohibits attempts to monopolize any part of the trade or commerce among the States.
- 154. Antech has substantial power in the relevant market for the diagnostic reference laboratory testing for animals and there exists a dangerous probability of Antech gaining monopoly power in this market.
- 155. With the specific intent to acquire monopoly power in and over the relevant market, Antech has committed exclusionary, or anticompetitive acts including the use of long-term exclusive dealing arrangements, the use of misleading financial incentive schemes, and intimidation tactics aimed to discourage the transmission of critical information about the quality and true cost of its services.
- 156. Rather than competing on price and the quality of the services it provides, Antech has attempted to foreclose competition through the use of

exclusive dealing arrangements and pricing schemes that allow it to distort the true cost of its services during the contracting process.

- 157. On information and belief, Antech has already established such arrangements with most of its veterinarian customers comprising approximately 45% of the veterinarians in the relevant market, and—if unchecked—Antech will foreclose even more of the market to competition.
- 158. Viewed in conjunction with similar exclusive dealing practices of IDEXX, the other large competitor in the relevant market, such exclusive dealing agreements currently foreclose 90% of the market to competition.
- 159. On information and belief, Antech's exclusive dealing arrangements, and its attempts to suppress the dissemination of information about the quality of its services, are having the effect of denying Antech's competitors meaningful market access and depriving them of the opportunity to achieve economies of scale.
- 160. Furthermore, because of Antech's conduct, consumers face a degradation in the quality of diagnostic reference laboratory testing for animals that would be available to them without Antech's anticompetitive conduct including its exclusive dealing arrangements, its confidentiality requirements, and other strong-arm tactics.
- 161. Upon information and belief, there are high barriers to entry in the relevant market for diagnostic reference laboratory testing services. These barriers include the exclusive dealing practices of Antech and IDEXX, the high concentration of market share held by these two firms, and the significant capital expenditures that are required to obtain land use permits, build testing facilities, and purchase expensive testing equipment that might quickly become obsolete in a rapidly developing technological environment.
- 162. Because Antech and IDEXX's agreements lock-up approximately 90% of the market for up to six years, and because a potential new competitor

- 163. Antech's anticompetitive conduct is not motivated by efficiency concerns and has no valid or legitimate business justification. Instead, its purpose and effect is to establish its monopoly position, and to diminish competition in the relevant market.
- 164. Antech's anticompetitive conduct alleged herein has injured (and unless enjoined, will continue to injure) consumers and competitors in the relevant market through unreliable laboratory testing, decreased choice, reduced innovation, and other anticompetitive effects, including raising additional barriers to entry in the relevant market.
- 165. By reason of Antech's unlawful attempted monopolization of the market for diagnostic reference laboratory testing services, Little Critters and other consumers in the relevant market have been injured in their business and property.
- 166. Unless enjoined and declared illegal, Antech's unlawful conduct will continue, consumers will continue to sustain injury and damages, and competition will continue to decrease in the relevant market.
- 167. The injuries to Little Critters and other consumers described herein are the types of injuries the antitrust laws were intended to prevent because they are a direct result of Antech's anticompetitive conduct alleged herein, which occurred in the United States, and has a substantial effect on competition in the relevant market.

28 | /////

/////

168. Plaintiffs are entitled to injunctive relief and to treble damages.

COUNT III Breach of Contract

- 169. Little Critters incorporate and reallege by reference each and every allegation above as if fully set forth herein.
- 170. Little Critters entered into the Contract with Antech. The Class entered into Exclusive Agreements with Antech.
- 171. Plaintiff Dr. Patt and Plaintiff Little Critters Vet, LLC are each parties to the Exclusive Agreement attached hereto, in pertinent part, as Exhibit A. The Exclusive Agreement explicitly identifies the parties as including Dr. Patt as the "practice owner," and Little Critters, LLC as the "practice" subject to the Contract's terms. Exh. A. Similarly, Dr. Patt signed the Contract, not merely personally, but under the denomination "Practice Owner." *Id.*, Page 2.
- 172. It is the evident intent of the parties to the Contract that it covers both Dr. Patt and Little Critters Vet, LLC. There is no doubt that the purpose of doing so was to enable Antech to proceed against either Dr. Patt or Little Critters Vet, LLC for contractual remedies.
- 173. Antech drafted the substantive terms of the Contract and the Exclusive Agreement, which were not subject to negotiation other than as to pricing, discount, and loan terms within a narrow range, and thus any ambiguity in such terms should be interpreted against Antech.
- 174. Paragraph 2 of the Standard terms and conditions in the Contract and Exclusive Agreements states, "All Laboratory Services provided by Antech Diagnostics pursuant to this Agreement are provided in accordance with and subject to all terms and conditions set forth in the ANTECH Service Directory in effect at the time the Laboratory Services are performed." Exh. A, Page 3, ¶ 2. The last Service Directory published by Antech states, "In accepting work, we warrant that we shall provide services in a professional manner by qualified

3 4

> 5 6

7 8

9 10

12 13

11

14 15

16

17

18

19 20

21 22

23

24

25 26

27

28

personnel, and we warrant the accuracy of the test results for the specimen submitted."

- Implied into every contract for professional or business services under California law is an implied duty, which cannot be waived that the services will be performed competently and with reasonable care.
- 176. Little Critters and the Class performed all material terms required under the Contract or Exclusive Agreements, respectively, or were excused from such performance by Antech's failure to perform adequately.
- 177. Little Critters demanded that Antech provide veterinary diagnostic reference laboratory testing services and results in a professional manner, with competence and reasonable care.
- Antech materially breached the Contract and Exclusive Agreements because it performed its part of the Contract to provide veterinary diagnostic reference laboratory testing services, unprofessionally, incompetently and with a failure to use reasonable care.
- 179. Under California law, every contract imposes upon each party a duty of good faith and fair dealing in its performance and enforcement. Antech's pattern of conduct related to Little Critters and the Class constituted objectively unreasonable conduct that unfairly failed to meet the reasonable expectations of the other parties to Antech's Exclusive Agreements. Antech's conduct includes failing to staff its diagnostic laboratories in the manner identified in the applicable guidelines, failing to manage the process and reporting of test results in the manner identified in the applicable guidelines, failing to communicate with the veterinarians in the manner identified in the applicable guidelines, changing written reports of lab results without following documentation protocols, and making statements to Little Critters and the Class which indicated the purpose of covering up the deficiencies in Antech's processes. Antech's overall conduct places at risk the entire careers and practices of the veterinarians who are subject

to Antech's Exclusive Agreements, forcing them to either continue using Antech's services after losing faith in the services provided or risk financial ruin when threatened by Antech. Antech's conduct in enforcing and threatening to enforce the exclusivity provisions of the agreements in the context of Antech's own failures is also unreasonable conduct.

- 180. Little Critters and the Class were harmed by Antech's conduct because Antech's woefully substandard performance required them to order and conduct extensive verifications, rechecks and pathology reviews of erroneous and potentially erroneous results, bearing the cost in time and money of doing same. Moreover, they were harmed by Antech's conduct because they had to either bear the risk of either a) terminating their agreement with Antech and facing Antech's threatened or actual litigation, or b) continuing to use the services of a veterinary diagnostic reference laboratory they no longer trusted at peril to their ethical duties, licenses, and liability, since veterinarians are primarily responsible for the level of care they provide to patients.
- 181. Little Critters and the Class are entitled to rescission of the Contract and to all Exclusive Agreements to which Class members exercise their right to rescind, and a declaration that they are not obligated to continue complying with the Exclusivity and Annual Minimum provisions of the Exclusive Agreements in particular, a declaration that Little Critters and the Class are not obliged to repay the value of the incentive payments or the "loan" included as part of the overall pricing scheme in the Exclusive Agreement.
- 182. Little Critters and the Class are entitled to an award of costs and attorneys' fees pursuant to California Civil Code, section 1717.

PRAYER FOR RELIEF

WHEREFORE, Little Critters and the Class demand judgment against Antech as follows:

1	
2	a
3	c
4	
5	Ċ
6	Ċ
7	f
8	l
9	
10	Ċ
11	
12	c
13	F
14	a
15	61
16	
17	r
18	
19	a
20	
21	
22	I
23	
24	
25	
26	
27	
28	
	1

- A. An order certifying that this action may be maintained as a class action, that Little Critters be appointed Class Representatives and Little Critters' counsel be appointed Class Counsel;
- B. A judgment awarding Little Critters and all members of the Class for damages, restitution or other equitable relief, including, without limitation, treble damages, disgorgement of all profits and unjust enrichment that Antech obtained from Little Critters and the Class as a result of the unlawful, unfair and fraudulent business practices described herein;
- C. An order enjoining Antech from continuing to violate the laws as described herein;
- D. A declaration that Little Critters and the Class are not required to continue compliance with the Exclusive and Annual Minimum provisions of their Exclusive Agreements with Antech in particular, a declaration that Little Critters and the Class are not obliged to repay the value of the incentive payments or the "loan" included as part of the overall pricing scheme in the Exclusive Agreement.
- E. A judgment awarding Little Critters the costs of suit, including reasonable attorneys' fees, and pre and post-judgment interest; and
- F. Such other and further relief as may be deemed necessary or appropriate.

JURY DEMAND

Little Critters demand trial by jury on all claims so triable.

DATED: July 17, 2020 GREEN & NOBLIN, P.C.

By: <u>/s/ Robert S. Green</u>
Robert S. Green

2200 Larkspur Landing Circle, Suite 101 Larkspur, CA 94939 Telephone: (415) 477-6700 Facsimile: (415) 477-6710

Email: gnecf@classcounsel.com

-57-

SECOND AMENDED COMPLAINT 8:18-CV-01689-JLS-DFM